SOUTH SAN FRANCISCO, Calif., May 16 CA-Anesiva-at-Citi-Co
SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva,
Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's
chief executive officer, will present at the Citi Investment Research Global
Healthcare Conference in New York City on May 22, 2008 at 9:30 a.m. EDT.
To access the live webcast or the subsequent archived recording, log on to
http://www.anesiva.com, go to the Investors page, and click on Events. Please
connect to Anesiva's website several minutes prior to the start of the webcast
to ensure adequate time for any software download that may be necessary.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be
the leader in the development and commercialization of novel pharmaceutical
products for pain management. The company has one FDA-approved product,
Zingo(TM), for the reduction of pain associated with peripheral venous access
procedures in children ages three to 18. In clinical trials, the most common
adverse reactions to Zingo were redness (erythema), red dots (petechiae) and
swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces
pain after only a single administration for weeks to months based on mid-stage
clinical trials for site-specific, acute and chronic, moderate-to-severe pain.
Anesiva is based in South San Francisco, CA. For more information about
Anesiva's leadership in the development of products for pain management, and
an overview of the clinical challenges being addressed by its product
candidates, go to http://www.anesiva.com.
SOURCE Anesiva, Inc.
